Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Valencia – page 88

1 777 clinical trials in Valencia, Spain across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Valencia at a glance
1 777
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

1 777 trials in Valencia

Open in trial search

Neurodermatitis

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Hormone-refractory prostate cancer+1

Not recruiting

Study of PF-06821497 with Enzalutamide for Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Bronchopulmonary aspergillosis

Not recruiting

Study on the Safety and Effectiveness of Opelconazole with Other Antifungal Treatments for Patients with Hard-to-Treat Lung Aspergillosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Opelconazole
  • Sponsor:Pulmocide Limited

Plasma cell myeloma refractory

Not recruiting

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Kite Pharma Inc.

Metastatic malignant melanoma

Not recruiting

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Transitional cell carcinoma

Not recruiting

Study on the Effects of 3 vs 6 Cycles of Platinum-based Chemotherapy and Avelumab in Patients with Advanced Urothelial Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Queen Mary University Of London

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Type 2 diabetes mellitus+2

Not recruiting

Study of NNC0519-0130 and semaglutide in people with chronic kidney disease who are overweight or obese, with or without type 2 diabetes

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Osimertinib and Datopotamab Deruxtecan for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Chronic graft versus host disease

Not recruiting

Study of Axatilimab for Patients with Chronic Graft Versus Host Disease After Two Prior Treatments

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Valencia

What the registry says about research in the country

01 Oncology & Hematology

Innovative research focused on Mantle Cell Lymphoma treatments and Immune Thrombocytopenia, evaluating novel therapeutic combinations and investigating new treatment approaches.

  • Lymphoma therapies
  • Blood disorders
  • Immunotherapy combinations

Studies aim to improve treatment outcomes and provide alternative therapeutic options for patients.

02 Respiratory Medicine

Comprehensive studies addressing Respiratory Syncytial Virus, ARDS, and COPD, with focus on innovative treatments and preventive measures.

  • Viral respiratory infections
  • Acute respiratory conditions
  • Vaccine development

Research emphasizes both therapeutic interventions and preventive strategies for respiratory diseases.

03 Neurology & Stroke

Advanced research into acute ischemic stroke treatments and outcomes, investigating novel therapeutic approaches for better patient recovery.

  • Stroke treatment
  • Neurological recovery
  • Reperfusion therapies

Focus on improving functional outcomes and reducing complications in stroke patients.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.